Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC
Introduction: BRAF mutations (present in 2%–3% of NSCLC) are a known oncogenic driver and emerging therapeutic target. There is a scarcity of real-world data describing the clinical characteristics, treatment patterns, and effectiveness of targeted BRAF-inhibiting and immune checkpoint inhibitor (IC...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-03-01
|
| Series: | JTO Clinical and Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364322001850 |
| _version_ | 1797855298123202560 |
|---|---|
| author | Amanda J.W. Gibson, BSc (Hons) Aliyah Pabani, MD Michelle L. Dean, BSc Guillermo Martos, MD Winson Y. Cheung, MD, MPH, FRCPC Vishal Navani, M.B.B.S., MRCP, FRACP |
| author_facet | Amanda J.W. Gibson, BSc (Hons) Aliyah Pabani, MD Michelle L. Dean, BSc Guillermo Martos, MD Winson Y. Cheung, MD, MPH, FRCPC Vishal Navani, M.B.B.S., MRCP, FRACP |
| author_sort | Amanda J.W. Gibson, BSc (Hons) |
| collection | DOAJ |
| description | Introduction: BRAF mutations (present in 2%–3% of NSCLC) are a known oncogenic driver and emerging therapeutic target. There is a scarcity of real-world data describing the clinical characteristics, treatment patterns, and effectiveness of targeted BRAF-inhibiting and immune checkpoint inhibitor (ICI)-based systemic therapies, yet this is required for appropriate treatment decisions that optimize patient outcome. Methods: Demographic, clinical, treatment, and outcome data of patients with BRAF mutation-positive NSCLC diagnosed between 2018 and 2022 were identified from the Glans-Look Lung Cancer Research database and included in this analysis. Results: A total of 53 BRAF mutation-positive patients were identified (V600E, n = 35; non-V600E, n = 18). Furthermore, 46 patients (87%) were diagnosed with metastatic disease, of whom 61% were treated with systemic anticancer therapy, which significantly improved overall survival (34.1 versus 2.2 mo, p = 0.01). ICI-based regimens were found to have effectiveness in the first-line setting for both V600E and non-V600E cohorts (objective response rate: 38%–43%; real-world calculations of median progression-free survival: 10.5–10.8 mo, respectively). Dual-targeted BRAF/MEK inhibition was also found to have effectiveness in the first-line setting for V600E patients (objective response rate: 33%, real-world calculations of median progression-free survival: 15.2 mo). Conclusions: This study of real-world patients with BRAF mutations confirms the importance of effective systemic therapies. Both dual-targeted BRAF/MEK inhibition and ICI-based regimens have evidence of benefit in this population revealing that real-world populations can experience similar clinical response and outcome to clinical trial cohorts on these treatment regimens. Future studies to clarify the role of co-mutations on response to both dual-targeted BRAF/MEK inhibition and ICI-based regimens may be important to treatment selection and optimization of patient outcome. |
| first_indexed | 2024-04-09T20:20:21Z |
| format | Article |
| id | doaj.art-e78d94bf195a4c678af18447c01445fa |
| institution | Directory Open Access Journal |
| issn | 2666-3643 |
| language | English |
| last_indexed | 2024-04-09T20:20:21Z |
| publishDate | 2023-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JTO Clinical and Research Reports |
| spelling | doaj.art-e78d94bf195a4c678af18447c01445fa2023-03-31T05:55:31ZengElsevierJTO Clinical and Research Reports2666-36432023-03-0143100460Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLCAmanda J.W. Gibson, BSc (Hons)0Aliyah Pabani, MD1Michelle L. Dean, BSc2Guillermo Martos, MD3Winson Y. Cheung, MD, MPH, FRCPC4Vishal Navani, M.B.B.S., MRCP, FRACP5Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Corresponding author. Address for correspondence: Amanda J. W. Gibson, BSc (Hons), Department of Oncology, Cumming School of Medicine, University of Calgary, 1331 29th Street Northwest, Calgary, AB T2N 4N2, Canada.Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Medical Oncology, Tom Baker Cancer Centre, Alberta Health Services, Calgary, Alberta, CanadaDepartment of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, CanadaDepartment of Medical Oncology, Tom Baker Cancer Centre, Alberta Health Services, Calgary, Alberta, CanadaDepartment of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Medical Oncology, Tom Baker Cancer Centre, Alberta Health Services, Calgary, Alberta, CanadaDepartment of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Medical Oncology, Tom Baker Cancer Centre, Alberta Health Services, Calgary, Alberta, CanadaIntroduction: BRAF mutations (present in 2%–3% of NSCLC) are a known oncogenic driver and emerging therapeutic target. There is a scarcity of real-world data describing the clinical characteristics, treatment patterns, and effectiveness of targeted BRAF-inhibiting and immune checkpoint inhibitor (ICI)-based systemic therapies, yet this is required for appropriate treatment decisions that optimize patient outcome. Methods: Demographic, clinical, treatment, and outcome data of patients with BRAF mutation-positive NSCLC diagnosed between 2018 and 2022 were identified from the Glans-Look Lung Cancer Research database and included in this analysis. Results: A total of 53 BRAF mutation-positive patients were identified (V600E, n = 35; non-V600E, n = 18). Furthermore, 46 patients (87%) were diagnosed with metastatic disease, of whom 61% were treated with systemic anticancer therapy, which significantly improved overall survival (34.1 versus 2.2 mo, p = 0.01). ICI-based regimens were found to have effectiveness in the first-line setting for both V600E and non-V600E cohorts (objective response rate: 38%–43%; real-world calculations of median progression-free survival: 10.5–10.8 mo, respectively). Dual-targeted BRAF/MEK inhibition was also found to have effectiveness in the first-line setting for V600E patients (objective response rate: 33%, real-world calculations of median progression-free survival: 15.2 mo). Conclusions: This study of real-world patients with BRAF mutations confirms the importance of effective systemic therapies. Both dual-targeted BRAF/MEK inhibition and ICI-based regimens have evidence of benefit in this population revealing that real-world populations can experience similar clinical response and outcome to clinical trial cohorts on these treatment regimens. Future studies to clarify the role of co-mutations on response to both dual-targeted BRAF/MEK inhibition and ICI-based regimens may be important to treatment selection and optimization of patient outcome.http://www.sciencedirect.com/science/article/pii/S2666364322001850BRAFImmune checkpoint inhibitorTargeted therapyOutcomesReal-world |
| spellingShingle | Amanda J.W. Gibson, BSc (Hons) Aliyah Pabani, MD Michelle L. Dean, BSc Guillermo Martos, MD Winson Y. Cheung, MD, MPH, FRCPC Vishal Navani, M.B.B.S., MRCP, FRACP Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC JTO Clinical and Research Reports BRAF Immune checkpoint inhibitor Targeted therapy Outcomes Real-world |
| title | Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC |
| title_full | Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC |
| title_fullStr | Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC |
| title_full_unstemmed | Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC |
| title_short | Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC |
| title_sort | real world treatment patterns and effectiveness of targeted and immune checkpoint inhibitor based systemic therapy in braf mutation positive nsclc |
| topic | BRAF Immune checkpoint inhibitor Targeted therapy Outcomes Real-world |
| url | http://www.sciencedirect.com/science/article/pii/S2666364322001850 |
| work_keys_str_mv | AT amandajwgibsonbschons realworldtreatmentpatternsandeffectivenessoftargetedandimmunecheckpointinhibitorbasedsystemictherapyinbrafmutationpositivensclc AT aliyahpabanimd realworldtreatmentpatternsandeffectivenessoftargetedandimmunecheckpointinhibitorbasedsystemictherapyinbrafmutationpositivensclc AT michelleldeanbsc realworldtreatmentpatternsandeffectivenessoftargetedandimmunecheckpointinhibitorbasedsystemictherapyinbrafmutationpositivensclc AT guillermomartosmd realworldtreatmentpatternsandeffectivenessoftargetedandimmunecheckpointinhibitorbasedsystemictherapyinbrafmutationpositivensclc AT winsonycheungmdmphfrcpc realworldtreatmentpatternsandeffectivenessoftargetedandimmunecheckpointinhibitorbasedsystemictherapyinbrafmutationpositivensclc AT vishalnavanimbbsmrcpfracp realworldtreatmentpatternsandeffectivenessoftargetedandimmunecheckpointinhibitorbasedsystemictherapyinbrafmutationpositivensclc |